Amedeo Smart

Free Medical Literature Service



Hepatitis C

  Free Subscription

Articles published in
    April 2021
  1. CHENG CY, Wu J
    Erythematous plaques on legs and feet in a patient with hepatitis C.
    Gastroenterology. 2021 Apr 1. pii: S0016-5085(21)00587.
    >> Share

    February 2021
  2. AWAD MT, Banifadel M
    Pustular Skin Lesions.
    Gastroenterology. 2021;160:675-676.
    >> Share

    January 2021
  3. ROCKEY DC, Friedman SL
    Fibrosis regression after eradication of hepatitis C virus - from bench to bedside.
    Gastroenterology. 2021 Jan 30. pii: S0016-5085(21)00330.
    >> Share

    May 2020
  4. KIM D, Konyn P, Cholankeril G, Wong RJ, et al
    Decline in Annual Mortality of Hepatitis C Virus-related Hepatocellular Carcinoma in the United States, From 2009 to 2018.
    Gastroenterology. 2020 May 7. pii: S0016-5085(20)30599.
    >> Share

  5. SINGAL AG, Parikh ND, Murphy CC
    Gastroenterology. 2020;158:1844.
    >> Share

    March 2020
  6. SALINAS E, Grakoui A
    Monkey in the Middle: Dynamics of Interspecies Antibody Responses.
    Gastroenterology. 2020;158:820-822.
    >> Share

    January 2020
  7. LO GH
    Did direct-acting antiviral therapy for hepatitis C virus infection really improve the survival of patients with hepatocellular carcinoma ?
    Gastroenterology. 2020 Jan 14. pii: S0016-5085(20)30102.
    >> Share

    December 2019
  8. CHEN F, Nagy K, Chavez D, Willis S, et al
    Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B cell-Based Vaccine Development.
    Gastroenterology. 2019 Dec 3. pii: S0016-5085(19)41871.
    >> Share

    Retreatment Options for Patients Who Failed Direct-Acting Antiviral Regimens Containing NS5A Inhibitors: Is Glecaprevir/Pibrentasvir a Valid and Robust Option?
    Gastroenterology. 2019;157:1473-1475.
    >> Share

    October 2019
  10. KIM D, Adejumo AC, Yoo ER, Iqbal U, et al
    Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017.
    Gastroenterology. 2019;157:1055-1066.
    >> Share

    August 2019
  11. LOK AS, Sulkowski MS, Kort JJ, Willner I, et al
    Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy.
    Gastroenterology. 2019 Aug 8. pii: S0016-5085(19)41199.
    >> Share

    Multi-omic Analyses Reveal Complex Interactions Between HCV and Hepatocytes Demonstrating That the Red Queen Is Up and Running.
    Gastroenterology. 2019;157:300-302.
    >> Share

    July 2019
  13. SINGAL AG, Rich NE, Mehta N, Branch A, et al
    Direct-Acting Antiviral Therapy for HCV Infection is Associated with Increased Survival in Patients With a History of Hepatocellular Carcinoma.
    Gastroenterology. 2019 Jul 30. pii: S0016-5085(19)41137.
    >> Share

  14. IOANNOU GN, Beste LA, Green PK, Singal AG, et al
    Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients with Baseline Cirrhosis or High FIB-4 Scores.
    Gastroenterology. 2019 Jul 26. pii: S0016-5085(19)41130.
    >> Share

    May 2019
  15. WING PAC, Jones M, Cheung M, DaSilva S, et al
    Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir.
    Gastroenterology. 2019 May 9. pii: S0016-5085(19)40865.
    >> Share

    April 2019
  16. LOHMANN V, Bartenschlager R
    Indelibly Stamped by Hepatitis C Virus Infection: Persistent Epigenetic Signatures Increasing Liver Cancer Risk.
    Gastroenterology. 2019 Apr 26. pii: S0016-5085(19)36726.
    >> Share

  17. LUPBERGER J, Croonenborghs T, Roca Suarez AA, Van Renne N, et al
    Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of HCV-infected Cells and Liver to Identify Pathways Associated With Disease Development.
    Gastroenterology. 2019 Apr 9. pii: S0016-5085(19)35670.
    >> Share

    March 2019
  18. SINGAL AG, Lim JK, Kanwal F
    AGA Clinical Practice Update on Interaction between Oral Direct-Acting Antivirals (DAAs) for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
    Gastroenterology. 2019 Mar 13. pii: S0016-5085(19)33558.
    >> Share

  19. HAMDANE N, Juhling F, Crouchet E, El Saghire H, et al
    HCV-induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.
    Gastroenterology. 2019 Mar 2. pii: S0016-5085(19)32506.
    >> Share

    February 2019
  20. TORRES HA, Pundhir P, Mallet V
    Hepatitis C virus infection in patients with cancer: impact on clinical trial enrollment, selection of therapy, and prognosis.
    Gastroenterology. 2019 Feb 21. pii: S0016-5085(19)30435.
    >> Share

  21. CACOUB P
    Hepatitis C Virus Infection, a New Modifiable Cardiovascular Risk Factor.
    Gastroenterology. 2019 Feb 15. pii: S0016-5085(19)30382.
    >> Share

  22. THABUT D, Bureau C, Layese R, Bourcier V, et al
    Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients with Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.
    Gastroenterology. 2019 Feb 12. pii: S0016-5085(18)35303.
    >> Share

    January 2019
  23. SINGAL AG, Rich NE, Mehta N, Branch A, et al
    Direct-Acting Antiviral Therapy not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
    Gastroenterology. 2019 Jan 17. pii: S0016-5085(19)30057.
    >> Share

  24. SALEM G, Adhikari LJ
    Hepatitis C, and Cannot See!
    Gastroenterology. 2019 Jan 2. pii: S0016-5085(18)35432.
    >> Share

    December 2018
  25. VERGARA C, Thio CL, Johnson E, Kral AH, et al
    Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.
    Gastroenterology. 2018 Dec 26. pii: S0016-5085(18)35421.
    >> Share

  26. ALTER HJ, Chisari FV
    Is Elimination of Hepatitis B and C a Pipe Dream or Reality?
    Gastroenterology. 2018 Dec 26. pii: S0016-5085(18)35422.
    >> Share

    November 2018
  27. BUTT AA, Yan P, Shuaib A, Abou-Samra AB, et al
    Direct-acting Antiviral Therapy for HCV Infection is Associated with a Reduced Risk of Cardiovascular Disease Events.
    Gastroenterology. 2018 Nov 13. pii: S0016-5085(18)35264.
    >> Share

  28. WARD JW, Hinman AR
    What is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats.
    Gastroenterology. 2018 Nov 1. pii: S0016-5085(18)35205.
    >> Share

  29. NAGAI S, Chau LC, Schilke RE, Safwan M, et al
    Effects of Allocating Livers for Transplantation Based on Model for End-Stage Liver Disease-Sodium Scores on Patient Outcomes.
    Gastroenterology. 2018;155:1451-1462.
    >> Share

    October 2018
  30. IOANNOU GN, Feld JJ
    What are the Benefits of a Sustained Virologic Response to Direct-acting Antiviral Therapy for HCV Infection?
    Gastroenterology. 2018 Oct 24. pii: S0016-5085(18)35166.
    >> Share

  31. BAUMERT TF, Berg T, Lim JK, Nelson DR, et al
    Status of Direct-acting Antiviral Therapy for HCV Infection and Remaining Challenges.
    Gastroenterology. 2018 Oct 17. pii: S0016-5085(18)35155.
    >> Share

  32. VISENTINI M, Fiorilli M, Casato M
    Persistence of pathogenic B cell clones and relapse of cryoglobulinemic vasculitis in HCV-cured patients.
    Gastroenterology. 2018 Oct 10. pii: S0016-5085(18)35150.
    >> Share

  33. O'BRIEN TR, Yang HI, Groover S, Jeng WJ, et al
    Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression.
    Gastroenterology. 2018 Oct 1. pii: S0016-5085(18)35083.
    >> Share

  34. KIM D, Li AA, Gadiparthi C, Khan MA, et al
    Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016.
    Gastroenterology. 2018;155:1154-1163.
    >> Share

  35. PERRY I, Patel D
    Hemoptysis: Call the Gastroenterologist?
    Gastroenterology. 2018;155:e1-e2.
    >> Share

    September 2018
  36. BAILEY JR, Barnes E, Cox AL
    Approaches, Progress, and Challenges to Hepatitis C Vaccine Development.
    Gastroenterology. 2018 Sep 26. pii: S0016-5085(18)35035.
    >> Share

  37. REHERMANN B, Thimme R
    Insights From Antiviral Therapy into Immune Responses to HBV and HCV Infection.
    Gastroenterology. 2018 Sep 26. pii: S0016-5085(18)35037.
    >> Share

    Re: Sofosbuvir, Velpatasvir, and Ribavirin in HCV.
    Gastroenterology. 2018 Sep 8. pii: S0016-5085(18)34936.
    >> Share

    August 2018
  39. BOYER A, Park SB, de Boer Y, Li Q, et al
    TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes.
    Gastroenterology. 2018 Aug 22. pii: S0016-5085(18)34892.
    >> Share

  40. OJHA RP, MacDonald BR, Chu TC, Marcus JL, et al
    Potential Overestimation of Racial Disparities in Response to the 8-Week Ledipasvir/Sofosbuvir Regimen for Hepatitis C Virus Genotype 1 Infection.
    Gastroenterology. 2018 Aug 14. pii: S0016-5085(18)34876.
    >> Share

    July 2018
  41. LUNEMANN S, Schobel A, Kah J, Fittje P, et al
    Interactions Between KIR3DS1 and HLA-F Activate Natural Killer Cells to Control HCV Replication in Cell Culture.
    Gastroenterology. 2018 Jul 19. pii: S0016-5085(18)34785.
    >> Share

  42. NAHON P, Layese R, Bourcier V, Cagnot C, et al
    Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
    Gastroenterology. 2018 Jul 18. pii: S0016-5085(18)34781.
    >> Share

  43. KOH S, Kah J, Tham CYL, Yang N, et al
    Nonlytic Lymphocytes Engineered to Express Virus-Specific T-Cell Receptors Limit HBV Infection by Activating APOBEC3.
    Gastroenterology. 2018;155:180-193.
    >> Share

    June 2018
  44. ESTEBAN R, Pineda JA, Calleja JL, Casado M, et al
    Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With HCV genotype 3 Infection and Cirrhosis.
    Gastroenterology. 2018 Jun 26. pii: S0016-5085(18)34684.
    >> Share

    May 2018
  45. GARDINI AC, Conti F, Brillanti S, Andreone P, et al
    Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals.
    Gastroenterology. 2018 May 7. pii: S0016-5085(18)30419.
    >> Share

  46. MOORMAN AC, Xing J, Nelson NP
    Need for Increasing Hepatitis A Virus Vaccination Among Patients Infected With Hepatitis B Virus and Hepatitis C Virus.
    Gastroenterology. 2018 May 3. pii: S0016-5085(18)34481.
    >> Share

  47. COSTENTIN C, Layese R, Bourcier V, Cagnot C, et al
    Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-time Adjusted Survival of Patients With Compensated Viral Cirrhosis.
    Gastroenterology. 2018 May 2. pii: S0016-5085(18)30488.
    >> Share

    April 2018
  48. BONACCI M, Lens S, Marino Z, Londono MC, et al
    Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure.
    Gastroenterology. 2018 Apr 26. pii: S0016-5085(18)30485.
    >> Share

  49. CALVARUSO V, Cabibbo G, Cacciola I, Petta S, et al
    Incidence of Hepatocellular Carcinoma in Patients with HCV-associated Cirrhosis Treated with Direct-Acting Antiviral Agents.
    Gastroenterology. 2018 Apr 12. pii: S0016-5085(18)30441.
    >> Share

  50. MORSE A, Barritt AS 4th, Jhaveri R
    Individual State Hepatitis C Data Supports Expanding Screening Beyond Baby Boomers to All Adults.
    Gastroenterology. 2018 Apr 2. pii: S0016-5085(18)30304.
    >> Share

  51. SCOTT RA, Aithal GP, Francis ST, Irving WL, et al
    Pretreatment Lesions on Magnetic Resonance Imaging in Patients With Hepatitis C Virus Infection Diagnosed With Hepatocellular Carcinoma After Initiating Direct-Acting Antiviral Therapy.
    Gastroenterology. 2018 Apr 2. pii: S0016-5085(18)30305.
    >> Share

    March 2018
  52. GRUNVOGEL O, Colasanti O, Lee JY, Kloss V, et al
    Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll Like Receptor 3 in Hepatocytes.
    Gastroenterology. 2018 Mar 10. pii: S0016-5085(18)30309.
    >> Share

  53. EL-SHERIF O, Jiang ZG, Tapper EB, Huang KC, et al
    Baseline Factors Associated with Improvements in Decompensated Cirrhosis After Direct-acting Antiviral Therapy for HCV Infection.
    Gastroenterology. 2018 Mar 10. pii: S0016-5085(18)30314.
    >> Share

  54. PONZETTO A, Figura N
    Risk of Hepatocellular Carcinoma After Cure of Hepatitis C Virus.
    Gastroenterology. 2018 Mar 8. pii: S0016-5085(18)30153.
    >> Share

  55. LO GH
    The Elevation of Hepatic Venous Pressure Gradient After Sustained Virologic Response in Hepatitis C Virus-Related Cirrhosis.
    Gastroenterology. 2018 Mar 8. pii: S0016-5085(18)30148.
    >> Share

  56. MANDORFER M, Reiberger T, Peck-Radosavljevic M
    Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response.
    Gastroenterology. 2018 Mar 8. pii: S0016-5085(18)30150.
    >> Share

    February 2018
  57. PHAM LV, Ramirez S, Gottwein JM, Fahnoe U, et al
    HCV Genotype 6a Escape from and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
    Gastroenterology. 2018 Feb 15. pii: S0016-5085(18)30212.
    >> Share

  58. TEDESCO D, Thapa M, Chin CY, Ge Y, et al
    Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic gammadelta T-cell Receptor-positive Cells and Pathogenesis of Cholestatic Liver Disease.
    Gastroenterology. 2018 Feb 15. pii: S0016-5085(18)30214.
    >> Share

  59. MA AT, Feld JJ
    Hepatitis B Reactivation With Hepatitis C Treatment: Bringing Some Clarity to the Black Box.
    Gastroenterology. 2018 Feb 6. pii: S0016-5085(18)30161.
    >> Share

  60. TAVIS JE, Lomonosova E
    NVR 3-778 Plus Pegylated Interferon-alpha Treatment for Chronic Hepatitis B Viral Infections: Could 1 + 1 = 3?
    Gastroenterology. 2018;154:481-482.
    >> Share

    January 2018
  61. MUTZ P, Metz P, Lempp FA, Bender S, et al
    HBV Bypasses the Innate Immune Response and Does not Protect HCV From Antiviral Activity of Interferon.
    Gastroenterology. 2018 Jan 31. pii: S0016-5085(18)30112.
    >> Share

  62. AGHEMO A, Colombo M
    Glecaprevir/Pibrentasvir: The Final Piece in the Hepatitis C Virus Treatment Puzzle?
    Gastroenterology. 2018 Jan 31. pii: S0016-5085(18)30100.
    >> Share

  63. YOSHIKAWA T, Ohana M, Fukuda A
    High fever after radiofrequency ablation of hepatocellular carcinoma.
    Gastroenterology. 2018 Jan 31. pii: S0016-5085(18)30134.
    >> Share

  64. MOORMAN AC, Xing J, Rupp LB, Gordon SC, et al
    Hepatitis B Virus Infection and Hepatitis C Virus Treatment in a Large Cohort of Hepatitis C-Infected Patients in the United States.
    Gastroenterology. 2018 Jan 19. pii: S0016-5085(17)36689.
    >> Share

    December 2017
  65. GOTTWEIN JM, Pham LV, Mikkelsen LS, Ghanem L, et al
    Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.
    Gastroenterology. 2017 Dec 21. pii: S0016-5085(17)36720.
    >> Share

    November 2017
  66. LIU CJ, Chuang WL, Sheen IS, Wang HY, et al
    Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected with HBV.
    Gastroenterology. 2017 Nov 21. pii: S0016-5085(17)36369.
    >> Share

  67. SHERMAN KE, Shah VH
    Viral Hepatitis: Knowledge and Treatments for HBV/HCV and Associated Transplantation and Neoplasia.
    Gastroenterology. 2017 Nov 14. pii: S0016-5085(17)36348.
    >> Share

  68. DIETZ J, Susser S, Vermehren J, Peiffer KH, et al
    Patterns of Resistance-associated Substitutions in Patients With Chronic HCV Infection Following Treatment with Direct-acting Antivirals.
    Gastroenterology. 2017 Nov 13. pii: S0016-5085(17)36353.
    >> Share

  69. DEBES JD, van Tilborg M, Groothuismink ZMA, Hansen BE, et al
    Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-acting Antivirals.
    Gastroenterology. 2017 Nov 1. pii: S0016-5085(17)36295.
    >> Share

    October 2017
  70. RATTAY T, Dumont P, Heinzow HS, Hutton DW, et al
    Cost-effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers.
    Gastroenterology. 2017 Oct 23. pii: S0016-5085(17)36275.
    >> Share

  71. JOHN M, Metwally M, Mangia A, Romero-Gomez M, et al
    TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C.
    Gastroenterology. 2017 Oct 6. pii: S0016-5085(17)36134.
    >> Share

    Liver MAIT Cells in Hepatitis C: Pathogenetic Role or Innocent Bystanders?
    Gastroenterology. 2017 Oct 4. pii: S0016-5085(17)36186.
    >> Share

    September 2017
  73. CHILDS-KEAN LM, Hong J
    Detectable Viremia at the End of Treatment With Direct-Acting Antivirals Can Be Associated With Subsequent Clinical Cure in Patients With Chronic Hepatitis C: A Case Series.
    Gastroenterology. 2017 Sep 4. pii: S0016-5085(17)35912.
    >> Share

    August 2017
  74. MAAN R, Feld JJ
    Risk for hepatocellular carcinoma after HCV antiviral therapy with direct-acting antivirals: case closed?
    Gastroenterology. 2017 Aug 31. pii: S0016-5085(17)36085.
    >> Share

  75. YU ML
    Resistance-Associated Substitutions in Short Duration of Interferon-Free Direct-Acting Antivirals for Hepatitis C.
    Gastroenterology. 2017 Aug 3. pii: S0016-5085(17)35886.
    >> Share

  76. BOLTE FJ, O'Keefe AC, Webb LM, Serti E, et al
    Intra-hepatic Depletion of Mucosal Associated Invariant T cells in Hepatitis C Virus-induced Liver Inflammation.
    Gastroenterology. 2017 Aug 2. pii: S0016-5085(17)35975.
    >> Share

    July 2017
  77. MISHRA P, Florian J, Peter J, Vainorius M, et al
    Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals.
    Gastroenterology. 2017 Jul 27. pii: S0016-5085(17)35956.
    >> Share

  78. LENS S, Alvarado E, Marino Z, Londono MC, et al
    Effects of All-oral Anti-viral Therapy on HVPG and Systemic Hemodynamics in Patients with Hepatitis C Virus-associated Cirrhosis.
    Gastroenterology. 2017 Jul 19. pii: S0016-5085(17)35922.
    >> Share

    June 2017
  79. KANWAL F, Kramer J, Asch SM, Chayanupatkul M, et al
    Risk of Hepatocellular Cancer in HCV Patients Treated with Direct Acting Antiviral Agents.
    Gastroenterology. 2017 Jun 19. pii: S0016-5085(17)35797.
    >> Share

  80. ENOMOTO M, Murakami Y, Kawada N
    Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction?
    Gastroenterology. 2017 Jun 2. pii: S0016-5085(17)35638.
    >> Share

  81. DE MARCO L, Pellicano R
    When to Search for Occult Infection After Eradication of Hepatitis C?
    Gastroenterology. 2017 Jun 2. pii: S0016-5085(17)35601.
    >> Share

    May 2017
  82. KANWAL F, Bacon BR, Beste LA, Brill JV, et al
    Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group.
    Gastroenterology. 2017;152:1588-1598.
    >> Share

  83. SINGH S, Muir AJ, Dieterich DT, Falck-Ytter YT, et al
    American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases.
    Gastroenterology. 2017;152:1544-1577.
    >> Share

    April 2017
  84. LAIDLAW SM, Marukian S, Gilmore RH, Cashman SB, et al
    Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent from Interferons.
    Gastroenterology. 2017 Apr 26. pii: S0016-5085(17)35530.
    >> Share

  85. JACOBSON IM, Lawitz E, Gane EJ, Willems BE, et al
    Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir In Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
    Gastroenterology. 2017 Apr 5. pii: S0016-5085(17)35399.
    >> Share

    March 2017
  86. HOWELL J, Thompson AJ
    Hepatocellular Carcinoma After Sustained Virologic Response: Leave No One Behind.
    Gastroenterology. 2017 Mar 28. pii: S0016-5085(17)30334.
    >> Share

  87. JACOBSON IM, Lim JK, Fried MW
    AGA Institute Clinical Practice Update: Care of Patients Who Have Achieved a Sustained Virologic Response (SVR) Following Antiviral Therapy for Chronic Hepatitis C Infection.
    Gastroenterology. 2017 Mar 23. pii: S0016-5085(17)30327.
    >> Share

  88. MISHRA P, Chen M
    Direct-Acting Antivirals for Chronic Hepatitis C: Can Drug Properties Signal Potential for Liver Injury?
    Gastroenterology. 2017 Mar 18. pii: S0016-5085(17)30295.
    >> Share

  89. SAADOUN D, Pol S, Ferfar Y, Alric L, et al
    Efficacy and Safety of Sofosbuvir plus Daclatasvir for Treatment of HCV-associated Cryoglobulinemia Vasculitis.
    Gastroenterology. 2017 Mar 10. pii: S0016-5085(17)30269.
    >> Share

  90. COMARMOND C, Garrido M, Pol S, Desbois AC, et al
    Direct-acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-induced Cryoglobulinemia Vasculitis.
    Gastroenterology. 2017 Mar 5. pii: S0016-5085(17)30235.
    >> Share

    February 2017
  91. AGHEMO A, Colombo M
    Response-Guided Duration of Directly Acting Antiviral Therapy for Chronic Hepatitis C: Back to the Future?
    Gastroenterology. 2017 Feb 27. pii: S0016-5085(17)30205.
    >> Share

  92. JACOBSON IM, Lawitz E, Kwo PY, Hezode C, et al
    Safety and Efficacy of Elbasvir/Grazoprevir in Patients with Hepatitis C Virus Infection and Compensated Cirrhosis: an Integrated Analysis.
    Gastroenterology. 2017 Feb 10. pii: S0016-5085(17)30150.
    >> Share

  93. MATSUURA K, Sawai H, Ikeo K, Ogawa S, et al
    Genome-wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.
    Gastroenterology. 2017 Feb 2. pii: S0016-5085(17)30130.
    >> Share

  94. RAVI S, Axley P, Jones D, Kodali S, et al
    Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis.
    Gastroenterology. 2017 Feb 1. pii: S0016-5085(16)35535.
    >> Share

    January 2017
  95. GANE EJ, Hyland RH, Yang Y, Svarovskaia E, et al
    Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
    Gastroenterology. 2017 Jan 27. pii: S0016-5085(17)30074.
    >> Share

  96. GOLDBERG D, Ditah IC, Saeian K, Lalehzari M, et al
    Changes in the Prevalence of Hepatitis C Virus Infection, Non-alcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients with Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
    Gastroenterology. 2017 Jan 11. pii: S0016-5085(17)30014.
    >> Share

    December 2016
  97. KOUTSOUDAKIS G, Perez-Del-Pulgar S, Forns X
    Occult Hepatitis C Virus Infection: Are We Digging Too Deep?
    Gastroenterology. 2016 Dec 27. pii: S0016-5085(16)35528.
    >> Share

  98. BOSON B, Denolly S, Turlure F, Chamot C, et al
    Daclatasvir Prevents Hepatitis C Virus by Blocking Transfer of Viral Genome to Assembly Sites.
    Gastroenterology. 2016 Dec 5. pii: S0016-5085(16)35447.
    >> Share

    November 2016
  99. LI F, Kaffenberger B, Hart PA
    An Unusual Rash During Evaluation for Chronic Pancreatitis.
    Gastroenterology. 2016 Nov 25. pii: S0016-5085(16)34961.
    >> Share

  100. COLPITTS CC, Baumert TF
    SMAD about HCV cell entry and pathogenesis of liver disease.
    Gastroenterology. 2016 Nov 23. pii: S0016-5085(16)35398.
    >> Share

  101. DONNELLY MC, Imlach SN, Abravanel F, Ramalingam S, et al
    Sofosbuvir and Daclatasvir Anti-Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient.
    Gastroenterology. 2016 Nov 21. pii: S0016-5085(16)34895.
    >> Share

  102. ELMASRY S, Wadhwa S, Bang BR, Cook L, et al
    Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
    Gastroenterology. 2016 Nov 9. pii: S0016-5085(16)35323.
    >> Share

  103. WANG W, Hakim MS, Nair VP, de Ruiter PE, et al
    Distinct Antiviral Potency of Sofosbuvir against Hepatitis C and E Viruses.
    Gastroenterology. 2016 Nov 1. pii: S0016-5085(16)35194.
    >> Share

    October 2016
  104. KOMATSU TE, Boyd S, Sherwat A, Tracy L, et al
    Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
    Gastroenterology. 2016 Oct 20. pii: S0016-5085(16)35241.
    >> Share

  105. LIANG TJ
    Hepatitis C Virus: from Obscurity to the Lasker.
    Gastroenterology. 2016 Oct 17. pii: S0016-5085(16)35233.
    >> Share

  106. KWO P, Gane E, Peng CY, Pearlman B, et al
    Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients with Chronic Hepatitis C Infection.
    Gastroenterology. 2016 Oct 5. pii: S0016-5085(16)35170.
    >> Share

  107. AGHEMO A, Buti M
    Hepatitis C Therapy: Game Over!
    Gastroenterology. 2016 Oct 1. pii: S0016-5085(16)35131.
    >> Share

    September 2016
  108. ZHANG F, Sodroski C, Cha H, Li Q, et al
    Infection of Hepatocytes with HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Upregulating SMAD6 and SMAD7.
    Gastroenterology. 2016 Sep 29. pii: S0016-5085(16)35128.
    >> Share

  109. NAHON P, Bourcier V, Layese R, Audureau E, et al
    Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
    Gastroenterology. 2016 Sep 15. pii: S0016-5085(16)35070.
    >> Share

    April 2016
  110. BARRESI L, Ligresti D, Traina M
    A Challenging Diagnosis for a Biliary Stricture.
    Gastroenterology. 2016 Apr 29. pii: S0016-5085(16)00215.
    >> Share

    February 2016
  111. SERFATY L
    Clinical implications of concomitant alcohol use, obesity and viral hepatitis.
    Gastroenterology. 2016 Feb 9. pii: S0016-5085(16)00139.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016